Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
PR Newswire —
SHELTON, Conn., Oct. 31, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and...
 
       
             
             
             
             
             
             
             
             
             
             
            